Difference between revisions of "Epratuzumab (LymphoCide)"
Jump to navigation
Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
||
Line 8: | Line 8: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
− | [[Category:Intravenous | + | [[Category:Intravenous medications]] |
[[Category:Immunotherapy]] | [[Category:Immunotherapy]] |
Revision as of 17:34, 25 July 2017
Mechanism of action
Anti-CD22 antibody
Preliminary data
Acute lymphocytic leukemia
- Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. PubMed link to original article